00:45 , Jun 5, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: May 2019

New Therapeutic Targets and Biomarkers: May 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May. Therapeutic targets are defined as any protein, gene or other molecule...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
17:52 , May 28, 2019 |  BC Innovations  |  Distillery Therapeutics

B. fragilis PSA for the prevention of Herpes simplex encephalitis

DISEASE CATEGORY: Infectious disease INDICATION: Encephalitis; herpes simplex virus (HSV) Mouse studies suggest B. fragilis PSA could help prevent encephalitis caused by HSV. In a mouse model of HSV encephalitis, pretreatment with B. fragilis PSA...
18:24 , Mar 29, 2019 |  BC Week In Review  |  Clinical News

Arvinas brings its first PROTAC to the clinic

Arvinas said it has started dosing metastatic castration-resistant prostate cancer patients in a Phase I trial of ARV-110, an oral androgen receptor-targeted PROTAC. Preliminary data are expected next half. Arvinas Inc. (NASDAQ:ARVN) said it believes...
22:14 , Mar 1, 2019 |  BioCentury  |  Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
19:49 , Feb 15, 2019 |  BC Week In Review  |  Clinical News

Xtandi reduces radiographic PFS by 61% in metastatic hormone-sensitive prostate cancer

Astellas Pharma Inc. (Tokyo:4503) and Pfizer Inc. (NYSE:PFE) reported that Xtandi enzalutamide plus androgen deprivation therapy (ADT) reduced the risk of radiographic progression or death, the primary endpoint, by 61% vs. ADT alone in the...
00:35 , Feb 1, 2019 |  BC Innovations  |  Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
21:20 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Clovis' Rubraca leads to 44% ORR in Phase II for CRPC

Clovis Oncology Inc. (NASDAQ:CLVS) said twice-daily oral Rubraca rucaparib led to a confirmed objective response rate (ORR) by investigator assessment of 44% in 25 evaluable patients with a BRCA1/2 mutation in the Phase II TRITON2...
22:47 , Oct 19, 2018 |  BC Extra  |  Clinical News

Clovis' Rubraca leads to 44% ORR in Phase II for CRPC

Clovis Oncology Inc. (NASDAQ:CLVS) said twice-daily Rubraca rucaparib led to a confirmed objective response rate (ORR) by investigator assessment of 44% in 25 evaluable patients with a BRCA1/2 mutation in the Phase II TRITON2 trial...
22:42 , Sep 13, 2018 |  BC Week In Review  |  Company News

Endocyte raises $175M

Endocyte Inc. (NASDAQ:ECYT) raised $175 million through the sale of 9.5 million shares at $18.50 in a follow-on underwritten by Jefferies, Wells Fargo, RBC Capital Markets and Wedbush. The price was a 2% discount to...